# A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZKLJ02 Injection in Healthy Chinese Research Participants

> **NCT07638098** · PHASE1 · COMPLETED · sponsor: **Yunnan Zhongke Longjin Biotechnology Co.,Ltd.** · enrollment: 50 (actual)

## Conditions studied

- Evaluate the Safety and Tolerability of ZKLJ02 Injection in Healthy Chinese Research Participants

## Interventions

- **DRUG:** 10 mg of ZKLJ02 for injection or placebo
- **DRUG:** 20 mg of ZKLJ02 for injection or placebo
- **DRUG:** 40 mg of ZKLJ02 for injection or placebo
- **DRUG:** 80 mg of ZKLJ02 for injection or placebo
- **DRUG:** 120 mg of ZKLJ02 for injection or placebo

## Key facts

- **NCT ID:** NCT07638098
- **Lead sponsor:** Yunnan Zhongke Longjin Biotechnology Co.,Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-11
- **Primary completion:** 2025-11-18
- **Final completion:** 2025-11-18
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07638098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07638098, "A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZKLJ02 Injection in Healthy Chinese Research Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07638098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*